A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

计划入组 20 人 · 首次发布于 2020 年 7 月 22 日

Healthetech, Inc. SMART Study

计划入组 56 人 · 首次发布于 2005 年 9 月 19 日

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

计划入组 160 人 · 首次发布于 2026 年 2 月 12 日

Antituberculosis therapeutics(AN2 Therapeutics, Inc.)

GTPase therapeutics (Perturba Therapeutics Inc.)

Cancer therapeutics(Mirna Therapeutics, Inc.)

KNIGHT THERAPEUTICS (USA), INC.

United States

Ohsu Knight Cancer Institute

United States

Sterling-Knight Pharmaceuticals, LLC

United States

Knight Therapeutics Acquires Sumitomo's Canadian Portfolio Including MYFEMBREE and ORGOVYX for C$25.4 Million

TAVALISSE® (Fostamatinib) Approved in Mexico for Chronic ITP Treatment

Knight Therapeutics Seeks Approval for Qelbree® (viloxazine) in Canada for ADHD Treatment